Achieving effective anticancer drug therapy requires achieving success in controlling at least three major physical properties: Toxicity within exposed cancer cells, delivery of the agent so as to exceed a threshold effective level of drug activity in the full anatomic extent of the cancer cell population, and limiting the side-effects affecting normal tissues. Recent preliminary data of our co-leaders indicates areas in which these critical barriers can be overcome. We found evidence for a severe limitation for effective drug penetration in pancreatic and perhaps other cancers. We developed new tools for a micro-anatomic understanding of drug delivery, methods to measure short-timed endpoints of drug effects, and ways to improve tumor-specific retention of delivered circulating agents. These developments create new opportunities addressed in our proposal. Our short-term Aims are to develop tools and understanding of the micro-anatomy and timing of drug penetration in GI cancers using patient and animal tumors, to manage better the toxicity of certain administered agents, and to improve drug delivery by and across the tumor vasculature. These studies are done in conjunction with four ongoing clinical trials (funded elsewhere) and may allow stratification of results from trials and the design of improved trials. Our long-term goal is to enable more efficacious treatment of GI cancers and to lay a foundation for using tissue-based drug-delivery assay as part of the routine lab accompaniments - the companion diagnostics - of cancer therapy.

Public Health Relevance

It is often said that cancers are frequently resistant to anti-cancer drugs. In most tumors, it is possible that this view is misleading. Improved delivery of anti-cancer drugs, and new test procedures so as to inform doctors about the progress towards effective delivery in individual patients, may provide fresh approach and improved treatment strategies for using a wide range of anti-cancer drugs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA062924-20
Application #
8559518
Study Section
Special Emphasis Panel (ZCA1-RPRB-M)
Project Start
Project End
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
20
Fiscal Year
2013
Total Cost
$340,582
Indirect Cost
$129,849
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Llosa, Nicolas J; Cruise, Michael; Tam, Ada et al. (2015) The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov 5:43-51
Eshleman, James R; Norris, Alexis L; Sadakari, Yoshihiko et al. (2015) KRAS and guanine nucleotide-binding protein mutations in pancreatic juice collected from the duodenum of patients at high risk for neoplasia undergoing endoscopic ultrasound. Clin Gastroenterol Hepatol 13:963-9.e4
Zhen, David B; Rabe, Kari G; Gallinger, Steven et al. (2015) BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. Genet Med 17:569-77
Patel, Kalpesh; Iacobuzio-Donahue, Christine A; Gormley, Paul E et al. (2015) Are we systematically under-dosing patients with fluorouracil? J Clin Oncol 33:e36-7
De Remigis, Alessandra; de Gruijl, Tanja D; Uram, Jennifer N et al. (2015) Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival. Int J Cancer 136:127-37
Sutcliffe, Catherine G; Schultz, Kathleen; Brannock, Julitta M et al. (2015) Do people know whether they are overweight? Concordance of self-reported, interviewer-observed, and measured body size. Cancer Causes Control 26:91-8
Black, Chelsea M; Armstrong, Todd D; Jaffee, Elizabeth M (2014) Apoptosis-regulated low-avidity cancer-specific CD8(+) T cells can be rescued to eliminate HER2/neu-expressing tumors by costimulatory agonists in tolerized mice. Cancer Immunol Res 2:307-19
Kojima, Masatsugu; Murata, Satoshi; Mekata, Eiji et al. (2014) Fusion protein of mutant B7-DC and Fc enhances the antitumor immune effect of GM-CSF-secreting whole-cell vaccine. J Immunother 37:147-54
Wu, Xinyan; Renuse, Santosh; Sahasrabuddhe, Nandini A et al. (2014) Activation of diverse signalling pathways by oncogenic PIK3CA mutations. Nat Commun 5:4961
Amato, Eliana; Molin, Marco Dal; Mafficini, Andrea et al. (2014) Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas. J Pathol 233:217-27

Showing the most recent 10 out of 633 publications